{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:13:33Z","timestamp":1785413613785,"version":"3.56.0"},"reference-count":62,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Jagiellonian University","award":["N42\/DBS\/000456"],"award-info":[{"award-number":["N42\/DBS\/000456"]}]},{"award":["N42\/DBS\/000456"],"award-info":[{"award-number":["N42\/DBS\/000456"]}],"id":[{"id":"https:\/\/ror.org\/03bqmcz70","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Amikacin remains a key agent in the treatment of severe and complicated infections due to its bactericidal activity and low risk of Clostridioides difficile infection. It retains activity against most aerobic Gram-negative bacteria, including multidrug-resistant Enterobacterales and Pseudomonas. However, its use is limited by nephrotoxicity and ototoxicity. Methods: This narrative review evaluates clinical indications, pharmacokinetic and pharmacodynamic properties, dosing strategies, therapeutic drug monitoring (TDM), and safety profile of amikacin in adult patients based on 56 selected publications. A total of 24 articles were identified through database searches (PubMed and Embase), complemented by 32 additional sources to provide clinical and pharmacological context. Results: Available evidence demonstrates considerable uncertainty regarding the comparative effectiveness of different monitoring strategies. Lower trough concentrations are generally associated with reduced nephrotoxicity; however, an optimal safety threshold has not been clearly established. Guideline-recommended targets vary substantially and are supported by low-quality evidence. Amikacin pharmacokinetics, tissue penetration and toxicity are influenced by patient-specific factors, including critical illness, renal function variability, and concomitant nephrotoxic therapy, particularly vancomycin. Ototoxicity remains an additional clinically relevant concern. Conclusions: Current evidence suggests that uniform dosing and monitoring paradigms are insufficient. Patient-tailored strategies integrating TDM and mitigation of modifiable risk factors are required. Prospective studies comparing monitoring regimens are needed to optimize the safe clinical use of amikacin and inform future guideline development.<\/jats:p>","DOI":"10.3390\/antibiotics15060534","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T02:32:28Z","timestamp":1779676348000},"page":"534","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Considerations of Amikacin Pharmacotherapy in Adults\u2014A Narrative Review with Focus on Safety and TDM"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4958-6909","authenticated-orcid":false,"given":"Daniel","family":"Orzechowski","sequence":"first","affiliation":[{"name":"Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Krakow, Poland"},{"name":"Department of Clinical Pharmacy, Ludwik Rydygier Memorial Specialized Hospital, 31-826 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4984-242X","authenticated-orcid":false,"given":"Aleksandra","family":"Mroczkowska","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Ludwik Rydygier Memorial Specialized Hospital, 31-826 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-2052","authenticated-orcid":false,"given":"Adrian","family":"Bry\u0142a","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Ludwik Rydygier Memorial Specialized Hospital, 31-826 Krakow, Poland"},{"name":"Department of Clinical Pharmacology, Chair of Pharmacology, Faculty of Medicine, Jagiellonian University Medical College, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0190-1682","authenticated-orcid":false,"given":"Anna","family":"Rapacz","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1080\/14656566.2021.1953472","article-title":"The role of amikacin in the treatment of nontuberculous mycobacterial disease","volume":"22","author":"Raaijmakers","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ramirez, M.S., and Tolmasky, M.E. (2017). Amikacin: Uses, Resistance, and Prospects for Inhibition. Molecules, 22.","DOI":"10.3390\/molecules22122267"},{"key":"ref_4","unstructured":"(2022). GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet, 400, 2221\u20132248."},{"key":"ref_5","unstructured":"Hryniewicz, W., Kuch, A., Wanke-Rytt, M., and \u017bukowska, A. (2026, January 22). Pa\u0142eczki Enterobacterales Wytwarzaj\u0105ce Karbapenemazy (CPE): Epidemiologia, Diagnostyka, Leczenie i Profilaktyka Zaka\u017ce\u0144, Available online: https:\/\/antybiotyki.edu.pl\/wp-content\/uploads\/Rekomendacje\/Rekomendacje-Pa%C5%82eczki-Enterobacterales_2023.21.02.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin. Infect. Dis.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/mdr.2019.0463","article-title":"In Vitro Activity of Ceftazidime-Avibactam Alone and in Combination with Amikacin Against Colistin-Resistant Gram-Negative Pathogens","volume":"27","author":"Chen","year":"2021","journal-title":"Microb. Drug Resist."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00003246-198805000-00010","article-title":"Hemodialysis of amikacin in critically ill patients","volume":"16","author":"Armstrong","year":"1988","journal-title":"Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0885066618754784","article-title":"Evaluation of Epithelial Lining Fluid Concentration of Amikacin in Critically Ill Patients with Ventilator-Associated Pneumonia","volume":"35","author":"Najmeddin","year":"2020","journal-title":"J. Intensive Care Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Viaggi, B., Cangialosi, A., Langer, M., Olivieri, C., Gori, A., Corona, A., Finazzi, S., and Di Paolo, A. (2022). Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review\u2014Part II. Antibiotics, 11.","DOI":"10.3390\/antibiotics11091193"},{"key":"ref_11","first-page":"4781","article-title":"Pharmacokinetics of amikacin in intra-abdominal sepsis","volume":"60","author":"Veringa","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","first-page":"493","article-title":"Therapeutic and adverse effects of aminoglycosides","volume":"32","author":"Vogelman","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","first-page":"45","article-title":"Pharmacokinetics of tissue penetration","volume":"27","author":"Bergan","year":"1981","journal-title":"Chemotherapy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e02098-19","DOI":"10.1128\/AAC.02098-19","article-title":"Population pharmacokinetic study of the suitability of standard dosing regimens of amikacin in critically ill patients with open-abdomen and negative-pressure wound therapy","volume":"64","author":"Carrie","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/eurheartj\/ehaf192","article-title":"2025 ESC Guidelines for the management of myocarditis and pericarditis","volume":"46","author":"Collini","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1128\/AAC.00277-11","article-title":"High-dose amikacin for achieving serum target levels in critically ill neonates: Insight into epithelial lining fluid penetration","volume":"55","author":"Tayman","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e02165-18","DOI":"10.1128\/AAC.02165-18","article-title":"A systematic review of single-dose aminoglycoside therapy for urinary tract infection: Is it time to resurrect an old strategy?","volume":"63","author":"Goodlet","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jiac.2014.08.007","article-title":"Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae","volume":"20","author":"Ipekci","year":"2014","journal-title":"J. Infect. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.32394\/pe.74.06","article-title":"Management of Clostridioides difficile infections including fecal microbiota transplantation","volume":"74","author":"Piekarska","year":"2020","journal-title":"Prz. Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"110874","DOI":"10.1016\/j.clinbiochem.2025.110874","article-title":"Amikacin therapeutic drug monitoring: Evaluation of therapy performance and analytical techniques in a developing country setting","volume":"136","author":"Steffens","year":"2025","journal-title":"Clin. Biochem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Aquino, M., Tinoco, M., Bicker, J., Falcao, A., Rocha, M., and Fortuna, A. (2023). Therapeutic Drug Monitoring of Amikacin in Neutropenic Oncology Patients. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020373"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/FTD.0000000000000621","article-title":"Amikacin Pharmacokinetics in Terminal Stage of Hematological Malignancy","volume":"41","author":"Nakayama","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13613-025-01461-z","article-title":"Amikacin use in critically ill patients requiring renal replacement therapy: The AMIDIAL-ICU study","volume":"15","author":"Dupont","year":"2025","journal-title":"Ann. Intensive Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1128\/AAC.00828-16","article-title":"Influence of renal replacement modalities on amikacin population pharmacokinetics in critically ill patients on continuous renal replacement therapy","volume":"60","author":"Roger","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"106219","DOI":"10.1016\/j.ejps.2022.106219","article-title":"Amikacin pharmacokinetics in elderly patients with severe infections","volume":"175","author":"Parada","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e02178-19","DOI":"10.1128\/AAC.02178-19","article-title":"Population pharmacokinetics of amikacin administered once daily in patients with different renal functions","volume":"64","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AAC.34.4.614","article-title":"Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity","volume":"34","author":"Garraffo","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/AAC.43.7.1549","article-title":"Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity","volume":"43","author":"Rybak","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40780-025-00438-1","article-title":"A preliminary retrospective study of the safety of vancomycin area under the curve in patients treated with concomitant use of vancomycin and gentamicin","volume":"11","author":"Nakayama","year":"2025","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.nephro.2018.08.004","article-title":"Interest of therapeutic drug monitoring of aminoglycosides administered by a monodose regimen","volume":"15","author":"Romdhane","year":"2019","journal-title":"Nephrol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"E52","DOI":"10.1503\/cmaj.140339","article-title":"Aminoglycoside-induced ototoxicity","volume":"187","author":"Leis","year":"2015","journal-title":"Can. Med. Assoc. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.mito.2010.10.006","article-title":"Mitochondrial 12S rRNA mutations associated with aminoglycoside ototoxicity","volume":"11","author":"Guan","year":"2011","journal-title":"Mitochondrion"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1128\/AAC.00965-08","article-title":"Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation","volume":"53","author":"Qian","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/cpt.2309","article-title":"Clinical Pharmacogenetics Implementation Consortium Guideline for Aminoglycoside-Induced Ototoxicity and MT-RNR1","volume":"111","author":"McDermott","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/thoraxjnl-2015-207245","article-title":"A systematic review and meta-analysis of the efficacy and safety of N-acetylcysteine in preventing aminoglycoside-induced ototoxicity: Implications for the treatment of multidrug-resistant TB","volume":"70","author":"Kranzer","year":"2015","journal-title":"Thorax"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/AAC.47.3.1010-1016.2003","article-title":"Aminoglycoside nephrotoxicity: Modeling, simulation, and control","volume":"47","author":"Rougier","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","first-page":"191","article-title":"Usage pattern and serum level measurement of amikacin in an internal medicine ward: A pharmacoepidemiological study","volume":"41","author":"Namazi","year":"2016","journal-title":"Iran. J. Med. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FTD.0000000000001279","article-title":"Dose optimization of amikacin in the emergency department: A population pharmacokinetics simulation study","volume":"47","author":"Dia","year":"2025","journal-title":"Ther. Drug Monit."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2147\/IDR.S150839","article-title":"High-dose amikacin for achieving serum target levels in critically ill elderly patients","volume":"11","author":"Sadeghi","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/fcp.12374","article-title":"Determinants of amikacin first peak concentration in critically ill patients","volume":"32","author":"Boidin","year":"2018","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1128\/AAC.01032-15","article-title":"Optimizing the initial amikacin dosage in adults: A retrospective evaluation of target attainment for pharmacokinetic\/pharmacodynamic indices","volume":"59","author":"White","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","first-page":"396","article-title":"Higher than recommended amikacin loading doses result in higher peak plasma levels but do not achieve target concentrations in all patients","volume":"38","author":"Luengo","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_43","first-page":"106124","article-title":"Aminoglycosides in critically ill patients: Which dosing regimens for which pathogens?","volume":"64","author":"Marsot","year":"2020","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Silva, J.Q.D., Moraes, N.V.D., Estrela, R., Coelho, D., Feriani, D., Migotto, K., Caruso, P., Silva, I.L.F.E., Oliveira, D.D.A., and Telles, J.P. (2025). Amikacin Dosing Adjustment in Critically Ill Oncologic Patients: A Study with Real-World Patients, PBPK Analysis, and Digital Twins. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17030297"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/FTD.0000000000001324","article-title":"A Bayesian Framework for Optimizing Amikacin Therapy in Critically Ill Patients With Cancer","volume":"47","author":"Yamamoto","year":"2025","journal-title":"Ther. Drug Monit."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00228-023-03516-1","article-title":"Failure to predict amikacin elimination in critically ill patients with cancer based on the estimated glomerular filtration rate: Applying PBPK approach in a therapeutic drug monitoring study","volume":"79","author":"Telles","year":"2023","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1128\/AAC.01314-10","article-title":"Optimization of aminoglycoside therapy","volume":"55","author":"Drusano","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","unstructured":"Gilbert, D.N., Chambers, H.F., Saag, M.S., Pavia, A.T., Boucher, H.W., Black, D., Freedman, D.O., Kim, K., and Schwartz, B.S. (2024). The Sanford Guide to Antimicrobial Therapy, Antimicrobial Therapy, Inc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jiac.2020.09.033","article-title":"A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity","volume":"27","author":"Yamada","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_50","first-page":"100990","article-title":"Amikacin in emergency surgery: How to dose it optimally?","volume":"41","author":"Goutelle","year":"2022","journal-title":"Anaesth. Crit. Care Pain Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Steffens, N.A., Zimmermann, E.S., Azeredo, F.J., Linden, R., Finatto, L.J., Hahn, R.Z., Schwarzbold, A.V., Pacheco, L.S., and Brucker, N. (2025). Therapeutic Drug Monitoring-Based Population Pharmacokinetics of Amikacin in Patients at a Teaching Hospital. Antibiotics, 14.","DOI":"10.3390\/antibiotics14060531"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1093\/jac\/dkw250","article-title":"Amikacin use and therapeutic drug monitoring in adults: Do dose regimens and drug exposures affect either outcome or adverse events? A systematic review","volume":"71","author":"Jenkins","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: A position paper","volume":"46","author":"Alffenaar","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_54","first-page":"493","article-title":"PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support","volume":"38","author":"Dujardin","year":"2019","journal-title":"Anaesth. Crit. Care Pain Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5414\/CN109761","article-title":"Nephrotoxicity of amikacin in noncritically ill patients","volume":"92","author":"Kim","year":"2019","journal-title":"Clin. Nephrol."},{"key":"ref_56","first-page":"40","article-title":"Effect of kidney function on amikacin pharmacokinetics in hospitalized patients: A knowledge to improve therapy","volume":"39","author":"Rocha","year":"2017","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/FTD.0000000000000800","article-title":"Impact of Therapeutic Drug Monitoring on Once-Daily Regimen of Amikacin in Patients with Urinary Tract Infection: A Prospective Observational Study","volume":"42","author":"Jayakumar","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/0976-0105.183260","article-title":"Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients","volume":"7","author":"Kovacevic","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/bcp.14542","article-title":"Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing","volume":"87","author":"Ryan","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Alhameed, A.F., Khansa, S.A., Hasan, H., Ismail, S., and Aseeri, M. (2019). Bridging the Gap between Theory and Practice; the Active Role of Inpatient Pharmacists in Therapeutic Drug Monitoring. Pharmacy, 7.","DOI":"10.3390\/pharmacy7010020"},{"key":"ref_61","first-page":"S87","article-title":"Is computer-assisted aminoglycoside dosing managed by a pharmacist a safety tool of pharmacotherapy?","volume":"68","author":"Tebbens","year":"2019","journal-title":"Physiol. Res."},{"key":"ref_62","first-page":"146","article-title":"Impact of amikacin pharmacokinetic\/pharmacodynamic target attainment on clinical outcomes in critically ill patients","volume":"30","author":"Grau","year":"2018","journal-title":"J. Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/6\/534\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:25:52Z","timestamp":1780547152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/6\/534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":62,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["antibiotics15060534"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15060534","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]}}}